全文获取类型
收费全文 | 19244篇 |
免费 | 1677篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 129篇 |
儿科学 | 746篇 |
妇产科学 | 574篇 |
基础医学 | 2849篇 |
口腔科学 | 417篇 |
临床医学 | 2542篇 |
内科学 | 3530篇 |
皮肤病学 | 233篇 |
神经病学 | 1833篇 |
特种医学 | 413篇 |
外国民族医学 | 1篇 |
外科学 | 2057篇 |
综合类 | 325篇 |
一般理论 | 19篇 |
预防医学 | 2374篇 |
眼科学 | 209篇 |
药学 | 1149篇 |
中国医学 | 18篇 |
肿瘤学 | 1525篇 |
出版年
2023年 | 115篇 |
2022年 | 82篇 |
2021年 | 335篇 |
2020年 | 302篇 |
2019年 | 451篇 |
2018年 | 467篇 |
2017年 | 371篇 |
2016年 | 396篇 |
2015年 | 407篇 |
2014年 | 592篇 |
2013年 | 898篇 |
2012年 | 1363篇 |
2011年 | 1452篇 |
2010年 | 780篇 |
2009年 | 726篇 |
2008年 | 1211篇 |
2007年 | 1254篇 |
2006年 | 1137篇 |
2005年 | 1137篇 |
2004年 | 1030篇 |
2003年 | 892篇 |
2002年 | 914篇 |
2001年 | 348篇 |
2000年 | 301篇 |
1999年 | 267篇 |
1998年 | 156篇 |
1997年 | 136篇 |
1996年 | 103篇 |
1995年 | 158篇 |
1994年 | 129篇 |
1993年 | 128篇 |
1992年 | 203篇 |
1991年 | 227篇 |
1990年 | 162篇 |
1989年 | 190篇 |
1988年 | 173篇 |
1987年 | 172篇 |
1986年 | 156篇 |
1985年 | 156篇 |
1984年 | 139篇 |
1983年 | 105篇 |
1982年 | 94篇 |
1981年 | 87篇 |
1980年 | 64篇 |
1979年 | 116篇 |
1978年 | 84篇 |
1975年 | 61篇 |
1974年 | 80篇 |
1973年 | 66篇 |
1972年 | 62篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
1.
In clinical and epidemiological studies, there is a growing interest in studying the heterogeneity among patients based on longitudinal characteristics to identify subtypes of the study population. Compared to clustering a single longitudinal marker, simultaneously clustering multiple longitudinal markers allow additional information to be incorporated into the clustering process, which reveals co-existing longitudinal patterns and generates deeper biological insight. In the current study, we propose a Bayesian consensus clustering (BCC) model for multivariate longitudinal data. Instead of arriving at a single overall clustering, the proposed model allows each marker to follow marker-specific local clustering and these local clusterings are aggregated to find a global (consensus) clustering. To estimate the posterior distribution of model parameters, a Gibbs sampling algorithm is proposed. We apply our proposed model to the primary biliary cirrhosis study to identify patient subtypes that may be associated with their prognosis. We also perform simulation studies to compare the clustering performance between the proposed model and existing models under several scenarios. The results demonstrate that the proposed BCC model serves as a useful tool for clustering multivariate longitudinal data. 相似文献
2.
Stephanie H. Ameis John D. Haltigan Rachael E. Lyon Amanda Sawyer Pat Mirenda Connor M. Kerns Isabel M. Smith Tracy Vaillancourt Joanne Volden Charlotte Waddell Lonnie Zwaigenbaum Teresa Bennett Eric Duku Mayada Elsabbagh Stelios Georgiades Wendy J. Ungar Anat Zaidman-Zait Meng-Chuan Lai Peter Szatmari for the Pathways in ASD Study Team 《Journal of child psychology and psychiatry, and allied disciplines》2022,63(5):553-562
3.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
4.
Rowan T. Chlebowski MD PhD Juhua Luo PhD Garnet L. Anderson PhD Wendy Barrington PhD Kerryn Reding PhD Michael S. Simon MD JoAnn E. Manson MD DrPh Thomas E. Rohan MBBS PhD Jean Wactawski-Wende PhD Dorothy Lane MD Howard Strickler MD Yasmin Mosaver-Rahmani PhD Jo L. Freudenheim PhD Nazmus Saquib MBBS PhD Marcia L. Stefanick PhD 《Cancer》2019,125(2):205-212
5.
Kerryn W. Reding Aaron K. Aragaki Richard K. Cheng Ana Barac Sylvia Wassertheil-Smoller Jessica Chubak Marian C. Limacher W. Gregory Hundley Ralph D'Agostino Jr. Mara Z. Vitolins Theodore M. Brasky Laurel A. Habel Eric J. Chow Rebecca D. Jackson Chu Chen April Morgenroth Wendy E. Barrington Matthew Banegas Matthew Barnhart Rowan T. Chlebowski 《The oncologist》2020,25(8):712-721
6.
Malinda Itchins Brandon Lau Amanda L. Hudson Helen Westman Cathy Yi Xia Sarah A. Hayes Viive M. Howell Michael Rodriguez Wendy A. Cooper Heng Wei Michael Buckland Bob T. Li Mark Li Vivek Rathi Stephen B. Fox Anthony J. Gill Stephen J. Clarke Michael J. Boyer Nick Pavlakis 《The oncologist》2020,25(8):641-649
7.
8.
Nur Zeinomar Kelly-Anne Phillips Mary B. Daly Roger L. Milne Gillian S. Dite Robert J. MacInnis Yuyan Liao Rebecca D. Kehm Julia A. Knight Melissa C. Southey Wendy K. Chung Graham G. Giles Sue-Anne McLachlan Michael L. Friedlander Prue C. Weideman Gord Glendon Stephanie Nesci kConFab Investigators Irene L. Andrulis Saundra S. Buys Esther M. John John L. Hopper Mary Beth Terry 《International journal of cancer. Journal international du cancer》2019,145(2):370-379
Benign breast disease (BBD) is an established breast cancer (BC) risk factor, but it is unclear whether the magnitude of the association applies to women at familial or genetic risk. This information is needed to improve BC risk assessment in clinical settings. Using the Prospective Family Study Cohort, we used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association of BBD with BC risk. We also examined whether the association with BBD differed by underlying familial risk profile (FRP), calculated using absolute risk estimates from the Breast Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) model. During 176,756 person-years of follow-up (median: 10.9 years, maximum: 23.7) of 17,154 women unaffected with BC at baseline, we observed 968 incident cases of BC. A total of 4,704 (27%) women reported a history of BBD diagnosis at baseline. A history of BBD was associated with a greater risk of BC: HR = 1.31 (95% CI: 1.14–1.50), and did not differ by underlying FRP, with HRs of 1.35 (95% CI: 1.11–1.65), 1.26 (95% CI: 1.00–1.60), and 1.40 (95% CI: 1.01–1.93), for categories of full-lifetime BOADICEA score <20%, 20 to <35%, ≥35%, respectively. There was no difference in the association for women with BRCA1 mutations (HR: 1.64; 95% CI: 1.04–2.58), women with BRCA2 mutations (HR: 1.34; 95% CI: 0.78–2.3) or for women without a known BRCA1 or BRCA2 mutation (HR: 1.31; 95% CI: 1.13–1.53) (pinteraction = 0.95). Women with a history of BBD have an increased risk of BC that is independent of, and multiplies, their underlying familial and genetic risk. 相似文献
9.
10.